Relapsed/Refractory Multiple Myeloma Clinical Trial Pipeline Expands as 55+ Companies Driving Innovation in Relapsed/Refractory Multiple Myeloma Therapeutics | DelveInsight

DelveInsight's, "Relapsed/Refractory Multiple Myeloma Pipeline Insight, 2025" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Relapsed/Refractory Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight's report, "Relapsing Refractory Multiple Myeloma Pipeline Insight 2025," offers a comprehensive and strategic review of the R&D landscape. It details clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as an essential reference for researchers, healthcare investors, and decision-makers, providing insights into the evolving RRMM therapeutics market and the breakthroughs shaping its future trajectory.

As relapsed/refractory multiple myeloma (RRMM) continues to rise globally and contributes to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is an increasing need for safer and more effective therapies. According to DelveInsight, the RRMM pipeline features over 55 pharmaceutical and biotech companies developing more than 60 therapeutic candidates across various stages of clinical and preclinical development, highlighting the significant innovation and dedication to tackling this critical public health issue.

Explore the Cutting-Edge Landscape of Relapsing refractory multiple myeloma Drug Development @ https://www.delveinsight.com/report-store/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Relapsing refractory multiple myeloma Pipeline Report
• DelveInsight's Relapsed/Refractory Multiple Myeloma (RRMM) pipeline report highlights a dynamic landscape with over 55 companies actively developing more than 60 therapeutic candidates for RRMM treatment.
• In April 2024, the FDA expanded the use of Abecma, permitting its administration earlier in the treatment sequence for RRMM patients who have undergone two or more prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Additionally, on August 9, 2023, the FDA approved talquetamab for adults with RRMM who have received at least four prior lines of therapy.
• Leading companies working on new RRMM treatments include Bristol-Myers Squibb, I-MAB Biopharma, Pfizer, Arcellx, Gilead Sciences, Novartis, Array Biopharma, Hrain Biotechnology Co., Ltd., Cartesian Therapeutics, Xencor, Takeda, Sorrento Therapeutics, Heidelberg Pharma AG, Ichnos Sciences, Allogene Therapeutics, Harpoon Therapeutics, Cellectis, Poseida Therapeutics, Regeneron Pharmaceuticals, ONK Therapeutics, TeneoOne, iTeos Therapeutics, Oricell Therapeutics, Anaveon AG, Luminary Therapeutics, Seagen Inc., Trillium Therapeutics Inc., Virtuoso BINco, Inc., and others, all aiming to enhance the RRMM treatment landscape.
• Promising pipeline therapies in various stages of development include Mezigdomide, Iopofosine, ORIC-533, and several additional candidates.

Relapsing refractory multiple myeloma Overview:
Multiple myeloma (MM) is a type of blood cancer characterized by the abnormal proliferation of monoclonal plasma cells in the bone marrow and, occasionally, other tissues. Relapsed/refractory multiple myeloma (RRMM) refers to cases where the disease returns after treatment or does not respond at all. Resistance often develops due to genetic mutations that help cancer cells evade therapies and alter their environment to protect themselves from the immune system.

Multiple Myeloma frequently begins as monoclonal gammopathy of undetermined significance (MGUS), a usually benign condition in which abnormal plasma cells are present without causing symptoms or organ damage. MGUS affects over 3% of individuals over the age of 50 and carries an approximate 1% annual risk of progressing to Multiple Myeloma.

Common symptoms of Multiple Myeloma include bone pain, fatigue, weight loss, and recurrent infections. Less frequent signs include hepatomegaly, splenomegaly, lymphadenopathy, and rare complications such as spinal cord compression or peripheral neuropathy, which may suggest related conditions like amyloidosis or POEMS syndrome.

Diagnosis follows NCCN guidelines and typically involves blood tests (CBC, kidney function, calcium, albumin, LDH, beta-2 microglobulin), serum and urine protein studies, and free light chain assays.

Treatment advances for RRMM include novel agents such as thalidomide, bortezomib, and lenalidomide, used alone or in combination with dexamethasone. These therapies have laid the groundwork for newer drugs like pomalidomide and carfilzomib, providing improved options for managing relapsed or refractory disease.

Download the Relapsing refractory multiple myeloma sample report to know in detail about the Relapsing refractory multiple myeloma treatment market @ https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Relapsing refractory multiple myeloma Pipeline Analysis
The Relapsing refractory multiple myeloma pipeline insights report 2025, provides insights into:
• Provides comprehensive insights into key companies developing therapies in the Relapsing refractory multiple myeloma Market.
• Categorizes Relapsing refractory multiple myeloma therapeutic companies by development stage: early, mid, and late-stage.
• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging Relapsing refractory multiple myeloma drugs under development based on:
o Stage of development
o Relapsing refractory multiple myeloma Route of administration
o Target receptor
o Monotherapy vs. combination therapy
o Relapsing refractory multiple myeloma Mechanism of action
o Molecular type

• Offers detailed analysis of:
o Company-to-company and company-academia collaborations
o Relapsing refractory multiple myeloma Licensing agreements
o Funding and investment activities supporting future Relapsing refractory multiple myeloma market advancement.

Unlock key insights into emerging Relapsing refractory multiple myeloma therapies and market strategies here: https://www.delveinsight.com/report-store/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Relapsing refractory multiple myeloma Emerging Drugs
• Mezigdomide: Bristol-Myers Squibb
Cereblon E3 ligase modulators (CELMoDs) are oral therapies that boost immune responses and destroy cancer cells by targeting and degrading proteins essential for tumor survival. Bristol Myers Squibb is advancing two next-generation CELMoDs, mezigdomide and iberdomide, for multiple myeloma treatment. These drugs are intended to provide greater effectiveness compared to current immunomodulatory agents (IMiDs), while offering manageable side effects, convenient oral administration, and the potential for improved patient outcomes.

• Iopofosine: Cellectar Biosciences, Inc.
Iopofosine is a small-molecule Phospholipid Drug ConjugateTM designed to deliver the radioisotope iodine-131 directly to cancer cells, reducing exposure to healthy tissues. This targeted mechanism differentiates iopofosine from many conventional therapies. It is currently under investigation in multiple studies, including the CLOVER-WaM Phase 2 pivotal trial for relapsed/refractory Waldenstrom's macroglobulinemia (r/r WM), a Phase 2b trial for relapsed/refractory multiple myeloma (r/r MM), and the CLOVER-2 Phase 1 study for various pediatric cancers.

Relapsing refractory multiple myeloma Pipeline Therapeutic Assessment
Relapsing refractory multiple myeloma Assessment by Product Type
• Mono
• Combination
• Mono/Combination

Relapsing refractory multiple myeloma By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Relapsing refractory multiple myeloma Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Relapsing refractory multiple myeloma Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download sample pages to get an in-depth assessment of the emerging Relapsing refractory multiple myeloma therapies and key Relapsing refractory multiple myeloma companies: https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Report Introduction
2. Executive Summary
3. Relapsing refractory multiple myeloma Current Treatment Patterns
4. Relapsing refractory multiple myeloma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Relapsing refractory multiple myeloma Late-Stage Products (Phase-III)
7. Relapsing refractory multiple myeloma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Relapsing refractory multiple myeloma Discontinued Products
13. Relapsing refractory multiple myeloma Product Profiles
14. Relapsing refractory multiple myeloma Key Companies
15. Relapsing refractory multiple myeloma Key Products
16. Dormant and Discontinued Products
17. Relapsing refractory multiple myeloma Unmet Needs
18. Relapsing refractory multiple myeloma Future Perspectives
19. Relapsing refractory multiple myeloma Analyst Review
20. Appendix
21. Report Methodology

Request the sample PDF to get detailed insights about the Relapsing refractory multiple myeloma pipeline reports offerings: https://www.delveinsight.com/report-store/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.